Chinook therapeutics revenue
WebApr 10, 2024 · An auction of Pear’s assets is expected to happen in early May. Pear Therapeutics’ search for a buyer has yet to lead to a consummated deal, and the … WebApr 9, 2024 · Chinook Therapeutics Trading Down 0.8 %. Shares of KDNY opened at $22.12 on Friday. The firm’s 50-day moving average is $23.02 and its two-hundred day moving average is $22.82.
Chinook therapeutics revenue
Did you know?
WebMay 12, 2024 · Revenue – Revenue for the quarter ended March 31, 2024 was $2.7 million compared to $0.4 million for the same period in 2024. The increase was primarily due to revenue recognized under Chinook ... WebApr 9, 2024 · The firm's quarterly revenue was down 90.0% on a year-over-year basis. Analysts predict that Chinook Therapeutics will post -3.19 EPS for the current year. Insider Transactions at Chinook Therapeutics. In related news, COO Tom Frohlich sold 4,566 shares of Chinook Therapeutics stock in a transaction on Tuesday, January 31st. The …
WebAug 8, 2024 · Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, provided a business update and reported financial results for the quarter and six months ended June 30, 2024. ... Revenue – Revenue for the quarter and six months ended … WebApr 14, 2024 · Chinook Therapeutics had a negative return on equity of 40.61% and a negative net margin of 3,065.68%. The firm’s revenue was down 90.0% on a year-over-year basis. As a group, analysts predict that Chinook Therapeutics, Inc. will post -3.19 earnings per share for the current year. Insider Activity
WebMar 25, 2024 · This is a summary of current ratings and price targets for Bio-Path and Chinook Therapeutics, as provided by MarketBeat. Bio-Path presently has a consensus price target of $9.00, indicating a ... WebApr 13, 2024 · Posted by Defense World Staff on Apr 13th, 2024. Chinook Therapeutics, Inc. ( NASDAQ:KDNY – Get Rating) gapped down before the market opened on …
WebFeb 27, 2024 · Chinook Therapeutics (KDNY) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to earnings of $0.14 per share a year ago. These ...
WebCumulative List of Organizations Described in Section 170 (c) of the Internal Revenue Code of 1954, Volumes 1-2. United States. Internal Revenue Service. Department of the … cycloplegic mechanism of actionWebChinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Changing the Course of Kidney Care™ Read More cyclophyllidean tapewormsWebFeb 25, 2024 · Chinook is headquartered in Berkeley, California, the US. The company reported revenues of (US Dollars) US$51.6 million for the fiscal year ended December 2024 (FY2024), compared to a revenue of US$0.8 million in FY2024. The operating loss of the company was US$99 million in FY2024, compared to an operating loss of US$83.9 … cycloplegic refraction slideshareWebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical … cyclophyllum coprosmoidesWebJun 2, 2024 · Conference Call Details. Chinook and Aduro will host a live conference call and webcast on Tuesday, June 2, 2024, at 8:30 am EDT to discuss the proposed transaction. To access the call, please ... cyclopiteWebApr 14, 2024 · The firm had revenue of $5.10 million during the quarter, compared to analyst estimates of $0.10 million. Chinook Therapeutics’s revenue was down 90.0% on a year-over-year basis. As a group, equities analysts forecast that Chinook Therapeutics will post -3.19 earnings per share for the current fiscal year. Insider Activity at Chinook … cyclop junctionsWebChinook Therapeutics revenue from 2014 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of … cycloplegic mydriatics